Combination treatment for non-hematologic malignancies

Abstract

The present invention relates to a therapeutic method for the treatment of non-hematologic malignancies comprising administering anti-IGF-1R antibodies, particularly human anti-IGF-1R antibodies, to a patient, in conjunction with the administration of at least one other therapeutic agent. The invention further relates to pharmaceutical compositions comprising these antibodies and methods of using such compositions thereof for treatment.

1 . A method for the treatment of lung cancer in a patient in need of such treatment comprising the step of administering to the patient a therapeutically effective amount of an antibody that specifically binds to IGF-1R in combination with a therapeutically effective amount of a taxane and a therapeutically effective amount of carboplatin, wherein the antibody is selected from the group consisting of 2.12.1, 2.13.2, 2.14.3, 4.9.2, 4.17.3, and 6.1.1. 
     
     
         2 . (canceled) 
     
     
         3 . The method of  claim 1 , wherein the taxane is docetaxel. 
     
     
         4 . The method of  claim 1 , wherein the taxane is paclitaxel. 
     
     
         5 - 16 . (canceled) 
     
     
         17 . The method according to  claim 1 , where in the amount of the antibody is in the range of 0.05-20 mg/kg. 
     
     
         18 . The method according to  claim 1 , where in the amount of the antibody is in the range of 0.5-10 mg/kg. 
     
     
         19 . The method according to  claim 4 , wherein the antibody is 2.13.2. 
     
     
         20 . The method according to  claim 4 , wherein the cancer is non-small cell lung cancer. 
     
     
         21 . A method of treatment for non-small cell lung cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of antibody 2.13.2 in combination of carboplatin and a therapeutically effective amount of paclitaxel. 
     
     
         22 . The method according to  claim 21 , wherein the amount of the antibody is in the range of 0.05-20 mg/kg. 
     
     
         23 . The method according to  claim 21 , wherein the antibody is administered once every two weeks, once every three weeks, or once every month.